• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

This product is currently not available for purchase.



  • ID: 1900083
  • August 2010
  • 64 Pages
  • VDM Publishing House

Malaria endemic countries are faced with a challenge of drug resistance to anti-malarial drugs. The switch to new malaria treatments using ACTs is costly.The rationale for this book is to analyze data aiming to answer the question regarding the effectiveness of three malaria treatments by using endpoints that consider healthcare utilization and access to care looking at the parents' initiative to seek medical care of their children otherthan the scheduled active follow ups in controlled clinical trials. Understanding patients' perception of their health in relation to anti-malarial drug regimens is important given the burden of costs of these drugs. It impact on the adherence to treatment and the motivation of patients to seek care which may led to drug resistance even with the newly developed drug. This books is useful to public health specialists, policy makers, statisticians and researchers in the health sector with an interest of coming up with sustainable malaria treatments, effective planning of policy changes and appropriate analysis of trials with multiple events

Note: Product cover images may vary from those shown

Phellister, Nakamya.
Phellister is an M and E/ Research Specialist at Malaria Consortium Uganda and Distance Learning Tutor of LSHTM for MSc Clinical Trials. She has MSc in Medical Statistics from LSHTM- University of London-2007 and B.STAT-2003 from Makerere University. She has previously worked with Wellcome Trust-Kenya working on Malaria, HIV/AIDs and Malnutrition.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

Our Clients

AB Sciex Eli Lilly and Company B. Braun Melsungen AG Astellas Pharma, Inc. Hologic Corporation Merck & Co., Inc.